Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silo Pharma Inc
(NQ:
SILO
)
2.460
-1.010 (-29.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Silo Pharma Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Silo Pharma (NASDAQ: SILO) Reports Positive Results from Dose Optimization Study for SPU-21 and Treatment of Arthritis
December 30, 2022
Silo Pharma, Inc. (NASDAQ: SILO) operates as a development-stage biopharmaceutical company, which is focused on combining traditional therapies with psychedelics
Via
Spotlight Growth
US Stocks Open Lower; Dow Drops 250 Points
December 30, 2022
U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Friday.
Via
Benzinga
Silo Pharma Stock Surges After Positive Study Results From Arthritis Study
December 30, 2022
Via
Benzinga
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
December 30, 2022
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END
Via
FinancialNewsMedia
Silo Pharma Announces Positive Study Results of SPU
December 30, 2022
21 for Arthritis – SPU-21 effective in controlling arthritis progression SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide Englewood Cliffs, – December...
Via
FinancialNewsMedia
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
December 30, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) CEO Discusses Advancement of Pipeline, Positioning in Shareholder Letter
December 01, 2022
Via
Investor Brand Network
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
December 01, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue
November 21, 2022
Via
Investor Brand Network
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
November 21, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
7 Millionaire-Maker Stocks You Will Regret Not Buying This Year
November 17, 2022
With the market shifting toward a deflationary stance, investors should target these robust millionaire-maker stocks to buy.
Via
InvestorPlace
Novel Psychedelic Compound For The Treatment Of Fibromyalgia Begins Dosing In Safety Trial
November 11, 2022
Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begu
Via
Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation
November 11, 2022
Via
Investor Brand Network
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
November 11, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
New Psychedelic Journal to Focus on Publishing Psychedelic Research
November 07, 2022
Via
Investor Brand Network
Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease
November 04, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation
November 03, 2022
Via
Investor Brand Network
Microscopy Provides Insights on Psychedelics Action Inside Neuropathways
October 28, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector
October 26, 2022
Via
Investor Brand Network
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
October 26, 2022
From
Silo Pharma, Inc.
Via
GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions
October 24, 2022
Via
Investor Brand Network
What You Should Know About Colorado’s Psychedelics Ballot Measure
October 24, 2022
Via
Investor Brand Network
Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway
October 24, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Data Supporting SPC-14’s Therapeutic Potential for Alzheimer’s
October 20, 2022
Via
Investor Brand Network
Exposures
Product Safety
What Is Going on With Silo Pharma (SILO) Stock Today?
October 20, 2022
Silo Pharma (SILO) stock is falling on Thursday despite the company releasing positive data from a pre-clinical Alzheimer's study.
Via
InvestorPlace
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
October 20, 2022
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which...
Via
FinancialNewsMedia
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
October 20, 2022
Dosing study of SPC-14 demonstrates efficacy for increasing memory function Englewood Cliffs, NJ – October 20, 2022 – Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...
Via
FinancialNewsMedia
Silo Pharma Posts Encouraging Preclinical Data For Alzheimer's Candidate
October 20, 2022
Silo Pharma Inc (NASDAQ: SILO) has announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD). The research was conducted as part of a...
Via
Benzinga
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
October 20, 2022
Dosing study of SPC-14 demonstrates efficacy for increasing memory function
From
Silo Pharma, Inc.
Via
GlobeNewswire
Psychedelics For Alzheimer's And Stress-Induced Disorders Under Study At Columbia University
October 18, 2022
Silo Pharma Inc.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.